ZA200003997B - Pharmaceutical compositions. - Google Patents

Pharmaceutical compositions.

Info

Publication number
ZA200003997B
ZA200003997B ZA200003997A ZA200003997A ZA200003997B ZA 200003997 B ZA200003997 B ZA 200003997B ZA 200003997 A ZA200003997 A ZA 200003997A ZA 200003997 A ZA200003997 A ZA 200003997A ZA 200003997 B ZA200003997 B ZA 200003997B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA200003997A
Other languages
English (en)
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200003997(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200003997B publication Critical patent/ZA200003997B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200003997A 2000-01-26 2000-08-04 Pharmaceutical compositions. ZA200003997B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA200003997B true ZA200003997B (en) 2000-08-14

Family

ID=9884259

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200003998A ZA200003998B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.
ZA200003997A ZA200003997B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200003998A ZA200003998B (en) 2000-01-26 2000-08-04 Pharmaceutical compositions.

Country Status (48)

Country Link
US (2) US6316460B1 (et)
EP (6) EP2266540A1 (et)
JP (3) JP3267960B2 (et)
KR (3) KR100388713B1 (et)
CN (3) CN101028268A (et)
AP (2) AP1449A (et)
AR (3) AR025055A1 (et)
AT (3) AT412062B (et)
AU (5) AU6580000A (et)
BE (2) BE1013414A5 (et)
BG (4) BG65234B1 (et)
BR (2) BR0003365A (et)
CA (3) CA2313783C (et)
CH (2) CH691347A5 (et)
CL (1) CL2007001807A1 (et)
CR (3) CR6568A (et)
CZ (3) CZ298411B6 (et)
DE (3) DE10038110B4 (et)
DK (3) DK200001170A (et)
EE (3) EE05586B1 (et)
ES (2) ES2155043B1 (et)
FI (3) FI111806B (et)
FR (2) FR2795324B1 (et)
GB (3) GB0001621D0 (et)
HK (6) HK1036934A1 (et)
HR (3) HRP20020097B1 (et)
HU (2) HU222578B1 (et)
IL (4) IL147870A (et)
IS (3) IS1940B (et)
IT (2) ITTO20000779A1 (et)
ME (4) ME00202B (et)
MY (2) MY122707A (et)
NL (2) NL1015858C2 (et)
NO (4) NO327675B1 (et)
NZ (2) NZ519774A (et)
PL (2) PL341855A1 (et)
PT (3) PT102504A (et)
RS (1) RS50201B (et)
RU (2) RU2206324C1 (et)
SE (2) SE523481C2 (et)
SI (1) SI1223918T1 (et)
SK (2) SK283872B6 (et)
TR (3) TR200200270T2 (et)
TW (2) TW553749B (et)
UA (2) UA51853C2 (et)
WO (2) WO2001054668A1 (et)
YU (1) YU52902A (et)
ZA (2) ZA200003998B (et)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6558659B2 (en) † 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
EP1541140A1 (en) * 2002-08-12 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
ES2401769T5 (es) * 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005056534A1 (en) * 2003-12-02 2005-06-23 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
EP2455067B1 (en) * 2004-05-04 2016-10-12 Innophos, Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
EP1673351A1 (en) * 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
AU2005271407A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CA2594017C (en) * 2005-02-22 2010-04-20 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR20080033410A (ko) * 2005-08-04 2008-04-16 트렌스폼 파마수티컬스 인코퍼레이티드 페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
AU2006309826B2 (en) * 2005-10-31 2012-01-19 Kowa Co., Ltd. Pharmaceutical preparation having excellent photostability
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
SI2024341T1 (sl) * 2006-05-03 2016-04-29 Msn Laboratories Private Limited Novi postopek za statine in njihove farmacevtsko sprejemljive soli
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
SI2086945T1 (sl) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novi postopek za pripravo statinov in njihovih farmacevtsko sprejemljivih soli
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
MX2009010925A (es) * 2007-04-09 2009-11-02 Scidose Llc Combinaciones de estatinas y agente anti-obesidad.
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
US20110003837A1 (en) * 2008-01-30 2011-01-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
EP2320876A2 (en) * 2008-06-13 2011-05-18 Pfizer Inc. Hydroxypropyl cellulose capsule shell
EP2138165A1 (en) * 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
AU2008358622A1 (en) * 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
WO2009156173A1 (en) * 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
EP2709592B1 (en) * 2011-05-20 2017-08-16 AstraZeneca UK Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
PL2851075T3 (pl) * 2012-05-14 2022-02-21 Shionogi & Co., Ltd. Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
MX2015012666A (es) * 2013-03-12 2016-02-16 Lg Life Sciences Ltd Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo.
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CA3007633A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
WO2018064630A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
UA29513C2 (uk) * 1995-12-22 2000-11-15 Кова Компані, Лтд Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
HUP0102260A3 (en) 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2396593A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
MEP33708A (en) 2010-10-10
ITTO20000779A1 (it) 2002-02-04
NO20003967D0 (no) 2000-08-04
JP2001206877A (ja) 2001-07-31
DE60001371D1 (de) 2003-03-13
AU781269C (en) 2006-11-30
SE523471C2 (sv) 2004-04-20
CN1319396A (zh) 2001-10-31
AP1879A (en) 2008-08-14
AR025055A1 (es) 2002-11-06
HU222578B1 (hu) 2003-08-28
HRP20080525A2 (en) 2008-12-31
FI20001749A (fi) 2001-07-27
IL147870A0 (en) 2002-08-14
TR200200270T2 (tr) 2002-06-21
IL150513A0 (en) 2003-02-12
NO2010005I1 (no) 2010-05-03
HK1048950A1 (zh) 2003-04-25
HRP20020632B1 (en) 2010-12-31
FI121365B (fi) 2010-10-29
CN101028268A (zh) 2007-09-05
IS2805B (is) 2012-09-15
BG66159B1 (bg) 2011-09-30
ITTO20000779A0 (it) 2000-08-04
IS1940B (is) 2004-07-16
CR6568A (es) 2004-03-05
AU781269B2 (en) 2005-05-12
HK1036935A1 (en) 2002-01-25
EP1251831A1 (en) 2002-10-30
WO2001054669A1 (en) 2001-08-02
AU2005202392C1 (en) 2016-06-02
EP2018853A1 (en) 2009-01-28
EP2133070A1 (en) 2009-12-16
CH700184B1 (de) 2010-07-15
US6548513B1 (en) 2003-04-15
EE200200052A (et) 2003-04-15
CN1282581A (zh) 2001-02-07
CR10114A (es) 2008-08-21
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
SK11792000A3 (sk) 2001-12-03
NO312434B1 (no) 2002-05-13
SE0002826D0 (sv) 2000-08-04
CZ20002883A3 (cs) 2000-10-11
CZ290167B6 (cs) 2002-06-12
ME00202B (me) 2010-10-10
GB0001621D0 (en) 2000-03-15
CL2007001807A1 (es) 2008-01-18
GB2358582A (en) 2001-08-01
ATA13612000A (de) 2004-02-15
DE60001371T2 (de) 2004-01-22
NL1015859C2 (nl) 2001-10-16
EE05586B1 (et) 2012-10-15
HU0003111D0 (en) 2000-10-28
CN1149997C (zh) 2004-05-19
TW553749B (en) 2003-09-21
DE10038110A1 (de) 2001-08-23
CZ299105B6 (cs) 2008-04-23
BG106393A (en) 2002-07-31
AU2000264559A1 (en) 2001-08-07
CZ298411B6 (cs) 2007-09-26
IS8620A (is) 2007-03-07
PT102503B (pt) 2004-02-27
SE0002827D0 (sv) 2000-08-04
DE10038110B4 (de) 2006-06-29
BG66168B1 (bg) 2011-10-31
EE05221B1 (et) 2009-10-15
NL1015858C2 (nl) 2001-07-27
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
CA2639407C (en) 2011-09-13
HUP0003111A2 (hu) 2002-02-28
EP1223918B1 (en) 2003-02-05
CA2313783C (en) 2002-03-12
PL341853A1 (en) 2001-01-29
KR100388713B1 (ko) 2003-06-25
NO327554B1 (no) 2009-08-10
MY123650A (en) 2006-05-31
DK200001170A (da) 2001-01-27
HRP20020097B1 (en) 2010-12-31
GB0019028D0 (en) 2000-09-27
ITTO20000780A1 (it) 2000-11-04
HK1040936B (zh) 2010-06-11
HK1200368A1 (en) 2015-08-07
TWI228050B (en) 2005-02-21
RU2264210C2 (ru) 2005-11-20
UA51853C2 (uk) 2002-12-16
IS6254A (is) 2002-01-29
SI1223918T1 (en) 2003-06-30
IL187416A0 (en) 2008-02-09
FI20001750A0 (fi) 2000-08-04
AU2005202392B2 (en) 2008-11-20
BE1013413A3 (fr) 2001-12-04
CA2639407A1 (en) 2001-07-26
FI20001749A0 (fi) 2000-08-04
FI20001750A (fi) 2001-07-27
JP2007182452A (ja) 2007-07-19
HUP0003111A3 (en) 2003-03-28
CH691347A5 (de) 2001-07-13
BG110353A (en) 2009-09-30
AR023624A1 (es) 2002-09-04
CA2315141A1 (en) 2001-07-26
TR200201888T2 (tr) 2002-11-21
AP2002002409A0 (en) 2002-03-31
AU5184200A (en) 2001-08-02
FI20105657A (fi) 2010-06-10
KR20000072135A (ko) 2000-12-05
SK283872B6 (sk) 2004-03-02
PT102504A (pt) 2001-07-31
JP2001206847A (ja) 2001-07-31
BG65234B1 (bg) 2007-09-28
ES2171123B1 (es) 2003-11-16
AP1449A (en) 2005-07-28
AU2005202392A1 (en) 2005-06-30
FR2795324A1 (fr) 2000-12-29
HUP0003110A2 (hu) 2001-05-28
NO20071303L (no) 2001-07-27
AT412063B (de) 2004-09-27
EE04990B1 (et) 2008-04-15
SE0002826L (sv) 2001-07-27
HU0003110D0 (en) 2000-10-28
NL1015859A1 (nl) 2001-07-27
KR20030036492A (ko) 2003-05-09
HK1036934A1 (en) 2002-01-25
DE10038108A1 (de) 2001-08-02
CA2315141C (en) 2009-08-18
AU5184100A (en) 2001-08-02
HRP20020632A2 (en) 2004-12-31
PT102503A (pt) 2000-12-29
BR0003365A (pt) 2001-09-18
PL341855A1 (en) 2001-07-30
SK11782000A3 (sk) 2001-12-03
ATE232088T1 (de) 2003-02-15
CA2313783A1 (en) 2000-10-16
KR20010077840A (ko) 2001-08-20
AU738074B2 (en) 2001-09-06
EE200900047A (et) 2011-04-15
NZ531474A (en) 2007-04-27
PT1223918E (pt) 2003-06-30
DK178242B1 (da) 2015-09-28
IS6480A (is) 2002-07-23
FR2804025A1 (fr) 2001-07-27
FR2804025B1 (fr) 2002-08-23
RU2002122752A (ru) 2004-03-10
NO20003968D0 (no) 2000-08-04
JP4800988B2 (ja) 2011-10-26
AR060248A2 (es) 2008-06-04
AT412062B (de) 2004-09-27
FR2795324B1 (fr) 2002-05-17
NO327675B1 (no) 2009-09-07
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
AU6580000A (en) 2001-08-07
EP1223918A1 (en) 2002-07-24
MY122707A (en) 2006-04-29
EE200200411A (et) 2003-12-15
RS50201B (sr) 2009-07-15
JP3267960B2 (ja) 2002-03-25
DK1223918T3 (da) 2003-04-28
BG106926A (bg) 2003-04-30
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
SE523481C2 (sv) 2004-04-20
EP2774609A1 (en) 2014-09-10
GB2358582B (en) 2004-09-29
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
YU52902A (sh) 2006-01-16
KR100698333B1 (ko) 2007-03-23
NO20003967L (no) 2001-07-27
BR0003364A (pt) 2001-09-18
IL150513A (en) 2012-12-31
ATA13602000A (de) 2004-02-15
ES2155043B1 (es) 2001-12-01
YU5202A (sh) 2004-12-31
HK1040936A1 (en) 2002-06-28
CZ20002884A3 (cs) 2001-09-12
AP2002002591A0 (en) 2002-09-30
FI111806B (fi) 2003-09-30
IL147870A (en) 2003-10-31
PL196808B1 (pl) 2008-02-29
BE1013414A5 (fr) 2001-12-04
NZ519774A (en) 2004-04-30
GB2358583B (en) 2002-02-06
HK1047052A1 (zh) 2003-02-07
GB0019029D0 (en) 2000-09-27
HUP0003110A3 (en) 2003-02-28
NO20003968L (no) 2001-07-27
CR6687A (es) 2005-07-18
DK200001171A (da) 2001-07-27
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
UA77156C2 (en) 2006-11-15
CN100528161C (zh) 2009-08-19
ES2171123A1 (es) 2002-08-16
EP2266540A1 (en) 2010-12-29
TR200701171T2 (tr) 2007-04-24

Similar Documents

Publication Publication Date Title
HK1036935A1 (en) Pharmaceutical compositions.
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
HUP0300582A3 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
ZA200101012B (en) Pharmaceutical combinations.
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200210359B (en) Pharmaceutical compositions.
HUP0400553A3 (en) Pharmaceutical compositions
MXPA03002105A (es) Composiciones farmaceuticas.
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
ZA200110500B (en) Pharmaceutical composition.
GB0005382D0 (en) Pharmaceutical composition
MXPA03007318A (es) Composicion farmaceutica.
ZA200110501B (en) Pharmaceutical composition.
ZA200110499B (en) Pharmaceutical composition.
ZA200303911B (en) Medicinal compositions.
GB0002691D0 (en) Pharmaceutical composition
GB0018321D0 (en) Pharmaceutical compositions
GB0001337D0 (en) Pharmaceutical compositions
GB0000062D0 (en) Pharmaceutical compositions
GB0031282D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions